155 related articles for article (PubMed ID: 38550296)
1. Cabozantinib Response in a Patient With NSCLC Harboring Both MET Exon 14 Skipping Mutation and Secondary RET Fusion: A Case Report.
Torrado C; Feng J; Faour E; Leighl NB
JTO Clin Res Rep; 2024 Apr; 5(4):100647. PubMed ID: 38550296
[TBL] [Abstract][Full Text] [Related]
2. Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation.
Fujino T; Suda K; Koga T; Hamada A; Ohara S; Chiba M; Shimoji M; Takemoto T; Soh J; Mitsudomi T
J Hematol Oncol; 2022 Jun; 15(1):79. PubMed ID: 35690785
[TBL] [Abstract][Full Text] [Related]
3. Safety of Tepotinib Challenge after Capmatinib-Induced Pneumonitis in a Patient with Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation: A Case Report.
Tseng LW; Chang JW; Wu CE
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233109
[TBL] [Abstract][Full Text] [Related]
4. FDA Approval Summary: Capmatinib and Tepotinib for the Treatment of Metastatic NSCLC Harboring MET Exon 14 Skipping Mutations or Alterations.
Mathieu LN; Larkins E; Akinboro O; Roy P; Amatya AK; Fiero MH; Mishra-Kalyani PS; Helms WS; Myers CE; Skinner AM; Aungst S; Jin R; Zhao H; Xia H; Zirkelbach JF; Bi Y; Li Y; Liu J; Grimstein M; Zhang X; Woods S; Reece K; Abukhdeir AM; Ghosh S; Philip R; Tang S; Goldberg KB; Pazdur R; Beaver JA; Singh H
Clin Cancer Res; 2022 Jan; 28(2):249-254. PubMed ID: 34344795
[TBL] [Abstract][Full Text] [Related]
5. Successful Tepotinib Challenge After Capmatinib-Induced Interstitial Lung Disease in a Patient With Lung Adenocarcinoma Harboring
Hashiguchi MH; Sato T; Yamamoto H; Watanabe R; Kagyo J; Domoto H; Shiomi T
JTO Clin Res Rep; 2022 Feb; 3(2):100271. PubMed ID: 35252894
[TBL] [Abstract][Full Text] [Related]
6. Tepotinib Efficacy in a Patient with Non-Small Cell Lung Cancer with Brain Metastasis Harboring an HLA-DRB1-MET Gene Fusion.
Blanc-Durand F; Alameddine R; Iafrate AJ; Tran-Thanh D; Lo YC; Blais N; Routy B; Tehfé M; Leduc C; Romeo P; Stephenson P; Florescu M
Oncologist; 2020 Nov; 25(11):916-920. PubMed ID: 32716573
[TBL] [Abstract][Full Text] [Related]
7. Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation.
Brazel D; Zhang S; Nagasaka M
Lung Cancer (Auckl); 2022; 13():33-45. PubMed ID: 35592355
[TBL] [Abstract][Full Text] [Related]
8. Selpercatinib and capmatinib combination promotes sustained complete response in novel
Leite CA; Carvalho RP; da Costa FM; Medeiros AK; Schutz FA; William WN
Front Oncol; 2023; 13():1264231. PubMed ID: 37876974
[No Abstract] [Full Text] [Related]
9. Effective treatment of
Kashizaki F; Okazaki S; Tsuchiya N; Chen H; Koizumi H; Takahashi K
AME Case Rep; 2024; 8():42. PubMed ID: 38711889
[TBL] [Abstract][Full Text] [Related]
10. Successful tepotinib treatment of adenocarcinoma with MET exon 14 skipping and discordant results between Oncomine Dx target test and ArcherMET: A case report.
Onodera Y; Sekine A; Hagiwara E; Yamada S; Ikeda S; Tabata E; Kitamura H; Baba T; Komatsu S; Okudela K; Ogura T
Mol Clin Oncol; 2023 Jun; 18(6):49. PubMed ID: 37228358
[TBL] [Abstract][Full Text] [Related]
11. Lazarus Response to Tepotinib for Leptomeningeal Metastases in a Patient With
Ninomaru T; Okada H; Fujishima M; Irie K; Fukushima S; Hata A
JTO Clin Res Rep; 2021 Mar; 2(3):100145. PubMed ID: 34590003
[TBL] [Abstract][Full Text] [Related]
12. Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies.
Wu YL; Smit EF; Bauer TM
Cancer Treat Rev; 2021 Apr; 95():102173. PubMed ID: 33740553
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer.
Drusbosky LM; Dawar R; Rodriguez E; Ikpeazu CV
J Hematol Oncol; 2021 Aug; 14(1):129. PubMed ID: 34425853
[TBL] [Abstract][Full Text] [Related]
14. The Treatment of a New Entity in Advanced Non-Small Cell Lung Cancer: MET exon 14 Skipping Mutation.
Rocco D; Della Gravara L; Palazzolo G; Gridelli C
Curr Med Chem; 2023 Aug; ():. PubMed ID: 37534484
[TBL] [Abstract][Full Text] [Related]
15. First-line tepotinib for a very elderly patient with metastatic NSCLC harboring
Inno A; Bogina G; Settanni G; Salgarello M; Foti G; Pomari C; Picece V; Gori S
Drug Target Insights; 2023; 17():110-113. PubMed ID: 37840886
[TBL] [Abstract][Full Text] [Related]
16. Matching-Adjusted Indirect Comparison (MAIC) of Tepotinib with Other MET Inhibitors for the Treatment of Advanced NSCLC with MET Exon 14 Skipping Mutations.
Paik PK; Pfeiffer BM; Vioix H; Garcia A; Postma MJ
Adv Ther; 2022 Jul; 39(7):3159-3179. PubMed ID: 35543963
[TBL] [Abstract][Full Text] [Related]
17. Dramatic response to neoadjuvant savolitinib in marginally resectable lung adenocarcinoma with MET exon 14 skipping mutation: A case report and literature review.
Tian J; Lin Z; Chen Y; Fu Y; Ding Z
Front Oncol; 2022; 12():1006634. PubMed ID: 36387081
[TBL] [Abstract][Full Text] [Related]
18. Dramatic intracranial response to tepotinib in a patient with lung adenocarcinoma harboring MET exon 14 skipping mutation.
Takamori S; Matsubara T; Fujishita T; Ito K; Toyozawa R; Seto T; Yamaguchi M; Okamoto T
Thorac Cancer; 2021 Mar; 12(6):978-980. PubMed ID: 33533182
[TBL] [Abstract][Full Text] [Related]
19. Absence of cross-toxicity between MET inhibitors in a non-small-cell lung cancer with a MET exon 14 skipping mutation.
Vanderick A; Colinet B
Acta Clin Belg; 2024 Apr; 79(2):148-151. PubMed ID: 38494868
[TBL] [Abstract][Full Text] [Related]
20. Management of Non-small Cell Lung Cancer Patients with MET Exon 14 Skipping Mutations.
Huang C; Zou Q; Liu H; Qiu B; Li Q; Lin Y; Liang Y
Curr Treat Options Oncol; 2020 Apr; 21(4):33. PubMed ID: 32306194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
